Check for updates

A systematic review of the inhibitory effect of extracts from edible parts of nuts on α-glucosidase activity†

Mena Farazi, [ID] Michael J. Houghton, [ID] ‡ Margaret Murray [ID] ‡ and Gary Williamson [ID] *

An elevated postprandial glycaemic response is a risk factor for developing type 2 diabetes mellitus (T2DM). Inhibition of digestive enzymes, including membrane-bound brush-border α-glucosidases, leads to slowed carbohydrate digestion and absorption, and reduced postprandial glycaemia. Nuts are eaten widely around the world, and have the potential to inhibit α-glucosidases through their content of polyphenols and other bioactive compounds. We set out to conduct a systematic literature review exploring the inhibitory effect of extracts from edible parts of various nuts on α-glucosidase activity *in vitro* to ensure, as far as possible, that no papers were missed. After an initial screening, 38 studies were reviewed in full, of which 15 were suitable for the present systematic review. Notably, no studies were found which tested the inhibitory potential of nut extracts against human α-glucosidases. Two studies showed that extracts from almonds and hazelnuts inhibited rat α-glucosidase activity, but the remaining papers reported data on the yeast α-glucosidase enzyme. Where yeast and rat enzymes can be compared, it is clear that nut extracts inhibit yeast α-glucosidase more strongly than mammalian α-glucosidase, which may lead to over-estimation when pre-dicting effects *in vivo* when using data from the yeast enzyme. In contrast, acarbose is a stronger inhibitor of mammalian α-glucosidase compared to the yeast enzyme. Thus, although the present review indicates that extracts from nuts inhibit yeast α-glucosidase, this cannot be extrapolated to humans *in vivo*. There is some evidence that extracts from almonds and hazelnuts inhibit rat α-glucosidase, but no information on human enzyme sources. Since most work has been published on the yeast enzyme, future work *in vitro* must utilise mammalian, and preferably human, α-glucosidases in order to be relevant to human health and disease. This systematic review was registered at INPLASY as INPLASY202280061.

1. Introduction

An elevated postprandial glycaemic response is a risk factor, and one of the initial signs, of type 2 diabetes mellitus (T2DM) that leads to increased oxidative stress and inflammation at various sites of the body.[1] Lowering the postprandial glycaemic response is an important dietary strategy to reduce the risk of T2DM.[2–4] Slowing down carbohydrate digestion by inhibition of salivary/pancreatic α-amylases and membrane-bound brush-border α-glucosidases has been shown to lower postprandial blood glucose responses.[5] Carbohydrates are rapidly digested by α-amylases and α-glucosidases to produce monosaccharides that

are absorbed in the small intestine into the blood. In the human small intestine, there are two brush border enzymes, maltase/glucoamylase and sucrase/isomaltase, exhibiting three α-glucosidase activities: maltase (hydrolysis of α-1,4-linkages between short chains of glucose), sucrase (hydrolysis of α-1,2-linkages between glucose and fructose as in sucrose) and isomaltase (hydrolysis of α-1,6-linkages between two glucose molecules). Dietary starches are hydrolysed firstly by salivary α-amylases, then by pancreatic α-amylases, and finally by intestinal brush border α-glucosidases to ultimately produce glucose.[6,7] Thus, the activities of these enzymes are a critical step in determining the postprandial glycaemic response, which can be attenuated by inhibition of these enzymes. Some anti-diabetic drugs, such as acarbose, are used to inhibit α-glucosidase to control postprandial glycaemia,[8,9] and it has been reported that various plant extracts can also inhibit α-glucosidase activity.[10–12]

Nut consumption is recommended in dietary guidelines worldwide because of health benefits.[13–15] Studies have shown that nut consumption lowers the risk of developing T2DM,[16] partly attributed to α-glucosidase activity inhibition.[17,18] While

Department of Nutrition, Dietetics and Food, School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing and Health Sciences, Monash University, BASE Facility, 264 Ferntree Gully Road, Notting Hill, VIC 3168, Australia.
E-mail: gary.williamson1@monash.edu; Tel: +61 3 99056649
†Electronic supplementary information (ESI) available. See DOI: https://doi.org/10.1039/d3fo00328k
‡Authors contributed equally.

several studies have indicated that consuming nuts is associated with a decreased risk of type 2 diabetes and metabolic syndrome,[19–23] there are some other studies which did not find any correlation between consuming nuts and a risk reduction.[24–26] According to a prospective cohort study,[22] individuals who ate 28 g of nuts 1–4 times per week, or >5 times per week, had a 16% and 27% statistically significant lower risk of diabetes, respectively, compared to those who rarely or never consumed nuts. As reported by Asghari *et al.*,[23] individuals who consumed 2–4 or ≥4 servings of nuts per week had a 49% and 53% lower risk of diabetes, respectively, in comparison to those who consumed <1 serving per week.

Nuts have a high total fat content (ranging from 44.4 g to 75.8 g per 100 g whole raw nut), but they are low in saturated fatty acids (3.8 g to 16.1 g per 100 g whole raw nut).[27,28] They are also an excellent source of protein (7.9 to 21.2 g per 100 g raw nut)[29] and dietary fibre (ranging from 4 to 11 g per 100 g whole raw nut),[27] which can provide 5–10% of the daily fibre requirements in standard servings.[30] Moreover, nuts have a favourable concentration of essential minerals, such as calcium, magnesium and potassium when compared to other commonly consumed foods.[27,31] Nuts are also abundant in vitamins and bioactive compounds such as tocopherols and polyphenols.[32–36] One action of some polyphenols, which are secondary metabolites produced by plants,[37–41] is to lower postprandial blood glucose[42] in the same way as acarbose.[7]

Certain flavonoids attenuate the activity of digestive enzymes[7,11] and are the major polyphenol class in nuts.[43] Data on the yeast α-glucosidase indicates that binding of the hydroxyl groups in ring A, B or C of flavonoids to the active sites of α-glucosidases results in subtle modifications of the enzyme structure[44–47] and inhibition is increased by hydroxylation of the A ring at the C5 or C6 of flavonoids.[11,48,49]

To ensure that we captured all papers on nut extracts and inhibition of α-glucosidase activity, we performed a systematic review of the literature. As we suspected prior to the search, most of the studies used yeast α-glucosidase despite indications in other literature that indicate that the specificity of inhibition of yeast and mammalian enzymes are very different.[10,11,50] This review should help shape future studies and ensure that *in vitro* data are better predictors on activity in human intervention studies.

2. Methods

This review was registered with the International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY) register of systematic reviews and is reported following the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement.[51]

2.1. Search strategy

The literature was searched, using a predetermined strategy, for published original studies that presented the effect of nut extracts on α-glucosidase activity. Articles were imported into Covidence (https://www.covidence.org) and duplicates were removed. The study selection was not limited to a period of time and all studies published up to the end of May 2022 were included for screening. All articles in this review were found from four different databases (PubMed, Scopus, Web of Science, and Cochrane) by searching the following research terms: ("inhibit*") AND ("nuts" OR "nut" OR "almond*" OR "pecan*" OR "pistachio*" OR "hazelnut*" OR "walnut*" OR "cashew*") AND ("*glucosidase" OR "sucrase*" OR "*maltase").

To be included, studies must have: (1) been written in English; (2) been original research; (3) tested compounds from the edible parts of nuts; and (4) measured α-glucosidase enzyme inhibition (specified as α-glucosidase, sucrase or maltase). There was no limitation on the source of α-glucosidase used and all studies that examined enzyme activity from yeast or mammalian sources were included.

2.2. Data extraction

Data were extracted independently by two authors (MF and MM) and verified by a third (MJH). Data regarding nut, test inhibitor, description of nut extraction method, number of replicates, source of enzyme and enzyme assay description, positive/negative controls, IC_{50}/inhibition% and range of inhibition, inhibition calculations, statistical analyses, and relevant outcomes were extracted from each paper.

2.3. Quality assessment

Two authors (MF and MJH) developed a quality assessment for *in vitro* enzyme assay studies, based on the ToxRTool,[52] and independently completed it. Briefly, the quality of the articles was evaluated against 17 criteria in five assessment domains: test substance identification, enzyme assay characterisation, study design description, study results documentation, and the plausibility of the study design and results. Each was given either a "yes" or "no" response (ESI Table 1†), however, because each criterion did not have the same significance, it was impossible to give each study an overall quality rating.

3. Results

3.1. Characteristics of the selected papers

The main objective of the present systematic review was to assess the literature on the inhibition of human α-glucosidase activity by bioactive compound extracts from nuts; however, the search included all sources of α-glucosidase and was not confined only to human enzymes. The search identified 531 papers and, after removing 163 duplicate papers, the titles and abstracts of 368 papers were screened by three reviewers (MF, MJH and MM) for inclusion. The same three reviewers independently assessed the full text of 38 articles against the inclusion criteria. Fig. 1 displays the search results and the study selection process. Full texts of all articles were obtained to retrieve detailed study characteristics. A total of 15 papers met all inclusion criteria;[17,18,53–65] 10 studies examined the

Fig. 1 PRISMA flow diagram for the systematic review, detailing the database searches, the number of abstracts screened, and full texts retrieved.

inhibitory effect on α-glucosidase activity of polyphenol-rich extracts, four studies examined the effects of isolated protein/peptides and one study used nuts extracted in hot water with no further extraction applied (Tables 1 and 2). Of the included studies, no studies reported the effect of nut extracts on human α-glucosidase, two studies examined rat α-glucosidase activity (Table 1), and 13 articles used α-glucosidase from yeast (Table 2). All studies presented the result of enzyme activity as either percentage of inhibition for a given concentration range or reported IC_{50}, defined as the concentration of extract necessary to inhibit enzyme activity by 50%. All studies conducted their analyses in triplicates except for Wang et al.,[64] who performed 5 replicates, and also Zhu et al.,[65] and Pino Ramos et al.,[61] who did not specify the number of replicates.

3.2. Inhibition of mammalian α-glucosidase by nut extracts

Table 1 presents the inhibitory potential of extracts from edible parts of almond (Prunus dulcis)[18] and hazelnut (Corylus avellana L.)[17] on rat α-glucosidase activity. Almond skin extract showed some inhibitory activity on rat intestinal maltase and sucrase, but the data was not compared to acarbose as a positive control.[18] Simsek isolated protein from hazelnut meal and hydrolysed this using two protease treatments, Alcalase or

trypsin/chymotrypsin, and studied the inhibitory effect of two peptide fractions from each (<5 kDa and >5 kDa). Several of the peptide fractions inhibited rat α-glucosidase activity by 50% at a concentration of ∼4 mg mL^{-1}. However, again due to the lack of a positive control, it is not possible to determine how hazelnut meal protein compared to acarbose.[17]

3.3. Inhibition of yeast α-glucosidase by nut extracts

Table 2 shows the inhibitory potential of extracts from edible parts of nuts on yeast α-glucosidase activity. Pino Ramos et al.[61] examined the effects of polyphenol-enriched extracts from raw and roasted hazelnuts from different regions of Chile. The mean IC_{50} for the extracts tested in this study, calculated from the 15 of 22 extracts where IC_{50} was determined, was 31.7 ± 30.4 μg mL^{-1}, with no apparent difference between raw or roasted, nor geographical region, while the acarbose positive control had an IC_{50} of 120.9 ± 2.0 μg mL^{-1}. The researchers identified 17 polyphenols in the extracts, mostly phenolic acid derivatives, though phenolic content was relatively low, and also some phytoprostanes and phytofurans.

Five of the included studies tested the inhibitory effects on yeast α-glucosidase of extracts from different types of almond. Of the polyphenol-rich extracts, Loizzo et al.[58] found the

Table 1 Characteristics of included studies which examined inhibition of rat α-glucosidase

Nut			Extraction		Rat enzyme assay				
Name	Part	Conditions		Target	Substrate	Positive control	Sample IC$_{50}$		Ref.
Almond (*Prunus dulcis*)	Roasted seed skin	Water, methanol, ethanol, acetone, acetonitrile		PP-rich	Maltose Sucrose	NS	468 µg DW mL^{-1} 627 µg DW mL^{-1}		18
Hazelnut (*Corylus avellana L.*)	Meal^a	Hexane, acetone, alkaline centrifugation, precipitation, alkaline protease hydrolysis, ultrafiltration		Purified peptides	*p*-Nitrophenyl-α-D-glucopyranoside	NS	3620 ± 720 µg DW mL^{-1} ^{b} 3890 ± 120 µg DW mL^{-1} ^{c} 4760 ± 120 µg DW mL^{-1} ^{d} ND^e		17

Data are expressed as mean (± standard deviation where specified) (*n* = 3). Abbreviations: NS, not specified; ND, no inhibition detected; PP, polyphenol. ^{a} No further details. ^{b} Alcalase samples (<5 kDa). ^{c} Trypsin + Chymotrypsin sample (<5 kDa). ^{d} Alcalase samples (>5 kDa). ^{e} Trypsin + Chymotrypsin sample (>5 kDa).

highest inhibitory potential with an extract from almond skin, similar to that of acarbose. LC-MS data revealed the almond skin extract contained at least 30 phenolics, including (+)-catechin, proanthocyanidin B, (−)-epicatechin, several quercetin and kaempferol glycosides, rosmarinic acid, and prunin. The data between the studies is difficult to compare, since different nut varieties, extraction methods, enzyme assay substrates and/or enzyme amounts were used in each. The water extract in the study by Attaallah *et al.*[55] demonstrated the lowest inhibition of yeast α-glucosidase by almonds, while water extracts of heckle seeds (*Ricinodendron heudelotii*), known commonly as the African nut-tree, also exhibited low inhibitory potential.[66] A fifth study on almonds involved testing peptides purified from the residue of almond oil from the Siberian apricot (*Armeniaca sibirica*), which belongs to a subgroup of the *Prunus* genus.[67] Hydrolysates, after digestion by two proteases, were purified in turn by gel filtration chromatography, reverse phase high performance liquid chromatography (RP-HPLC), molecular sieve and RP-HPLC again, with the inhibitory potential reaching 0.58 ± 0.02 µg mL^{-1} for a single isolated peptide.[57]

The inhibitory effects of polyphenol-rich extracts from eight pistachio cultivars, grown on the same farm in Spain, were studied by Noguera-Artiaga *et al.*[60] The inhibitory potential varied widely, with IC$_{50}$ values ≥2.5 mg mL^{-1} for four of the cultivars, while the other four cultivars exhibited an IC$_{50}$ value <5 µg mL^{-1}. Without a positive control for reference, it is difficult to comment on the relative potency of pistachio components as inhibitors of yeast α-glucosidase.

Zhu *et al.*,[65] studied the inhibitory effects of extracts from Chinese nutmeg yew (*Torreya grandis*), which is an evergreen and high-value medicinal plant. In this study, polyphenols were extracted from the kernels with ethanol, ranging from 10 to 90% (v/v), with 70% ethanol giving the richest phenolic content and showing the highest inhibition against yeast α-glucosidase activity (IC$_{50}$: 600 ± 30 µg mL^{-1}). This extract was purified further and the dichloromethane fraction showed the highest inhibition (IC$_{50}$: 20 ± 00 µg mL^{-1}) compared to an IC$_{50}$ of 760 ± 10 µg mL^{-1} for acarbose. In another study, Terebinth (*Pistacia terebinthus*), which is a type of deciduous shrub native

to the Mediterranean region, was extracted with hexane, acetone and ethanol. Again, findings indicate that these extracts had a higher inhibition potential (IC$_{50}$ ≤ 1580 µg mL^{-1}) than acarbose (IC$_{50}$: 10 300 µg mL^{-1}) on yeast α-glucosidase.[54] Wang *et al.*,[63,64] examined the inhibitory effect of protein isolated from Manchurian walnut (*J. mandshurica Maxim.*), in 2018 and 2020. Both studies found protein isolated from the walnuts was less effective than acarbose at inhibiting yeast α-glucosidase.

3.4. Comparison of yeast and mammalian α-glucosidase inhibition

Table 3 shows the inhibitory effects of almond and hazelnut extracts on rat and yeast α-glucosidase activity. These papers were the only types of nuts for which studies had been done using both yeast and rat enzymes. Polyphenol-rich extracts from hazelnuts showed 50% inhibition of yeast α-glucosidase activity at a mean concentration of 21.1 ± 14.6 µg mL^{-1} for raw samples and 33.4 ± 32.2 µg mL^{-1} for roasted samples,[61] whereas 50% inhibition of rat α-glucosidase with hazelnut meal peptides was found at much higher concentrations (3755 ± 191 µg mL^{-1}).[17] This demonstrates that hazelnut extracts are stronger inhibitors of yeast α-glucosidase compared to rat. However, it is worth noting that this is a comparison of polyphenol-rich extracts to purified peptides and the study by Simsek did not measure acarbose as a positive control,[17] and neither provided specific enzyme activities. A more definitive comparison can be made for almonds, since both studies used a polyphenol-rich almond skin extract with maltase as substrate. An 8-fold stronger inhibition potential towards yeast α-glucosidase[58] is evident compared to rat α-glucosidase.[18]

3.5. Quality assessment

ESI Table 1† shows the quality assessment of the papers included in the current review. Seventeen criteria were independently checked by two authors (MF and MJH). There were several key elements missing from the studies. Among the 15 reviewed studies, two did not specify the part of the nut from which the test substance/compounds was extracted[56,60] and two more did not provide information on the purity, nor any

Table 2 Characteristics of included studies which examined inhibition of yeast α-glucosidase

Nut		Extraction	Target	Yeast enzyme assay			Samples concentration range tested	Ref.
Name	Part	Conditions		Substrate	Positive control (IC$_{50}$ or inhibition (%))	Sample IC$_{50}$ or inhibition (%)		
Chilean hazelnut (*Gevuina avellana*)[d]	Seed[c]	Acetic acid, FeCl$_3$·6H$_2$O, acetonitrile, methanol	PP-rich	*p*-Nitrophenyl-α-D-glucopyranoside	Acarbose (120.9 ± 2.0 µg mL^{-1})	ND	0–100 µg DW mL^{-1} [b]	61
Vilches, 2016 raw[e]						31.4 ± 1.6 µg DW mL^{-1}		
Vilches, 2017 raw[e]						24.8 ± 0.7 µg DW mL^{-1}		
Vilches, 2016 roasted[e]						10.8 ± 0.9 µg DW mL^{-1}		
Los Lleques, 2017, April, raw[f]						ND		
Los Lleques, 2017, May, raw[f]						79.7 ± 2.6 µg DW mL^{-1}		
Los Lleques, 2016, roasted[f]						17.5 ± 0.4 µg DW mL^{-1}		
Los Lleques, 2017, April, roasted[f]						ND		
Los Lleques, 2016, mild to medium roasted (meal)[f]						66.5 ± 5.3 µg DW mL^{-1}		
Yungay, 2016, mild to medium roasted (meal)[g]						12.3 ± 0.7 µg DW mL^{-1}		
Contulmo, 2017, raw[h]						ND		
Contulmo, 2016, mild to medium roasted (meal)[h]						ND		
Contulmo, 2016, intensively roasted ("coffee")[h]						ND		
Cotulmo, 2016, callana roasted[h]						37.6 ± 2.6 µg DW mL^{-1}		
Contulmo, 2016, April, callana roasted[h]						5.0 ± 0.4 µg DW mL^{-1}		
Contulmo, 2017, April, callana roasted[h]						8.5 ± 0.6 µg DW mL^{-1}		
Contulmo, 2017, May, callana roasted[h]						7.9 ± 0.4 µg DW mL^{-1}		
Contulmo, 2016, April, tostador roasted[h]						87.4 ± 0.6 µg DW mL^{-1}		
Contulmo, 2016, May, tostador roasted[h]						76.4 ± 0.5 µg DW mL^{-1}		
Contulmo, 2017, April, tostador roasted[h]						3.7 ± 0.3 µg DW mL^{-1}		
Contulmo, 2017, May, tostador roasted[h]						6.6 ± 0.3 µg DW mL^{-1}		
Llanada Grande, 2018, raw[i]						60.9 ± 1.1% at 100 µg DW mL^{-1} [a]		
Indian almond (*Terminalia catappa* L.)	Shelled drupe	Methanol and N HCl	PP-rich	*p*-Nitrophenyl-α-D-glucopyranoside	NS	83.3 ± 3.5 µg DW mL^{-1}	40–160 µg[o]	53
Almond (*Prunus amygdalus*, syn. *Prunus dulcis*)	Cake[c]	Water, hexane, alkaline protease	PP-rich	*p*-Nitrophenyl-α-D-glucopyranoside	NS	84.6% at 500 µg DW mL^{-1} [a] 97.8% at 2000 µg DW mL^{-1} [a] 98.9% at 5000 µg DW mL^{-1} [a]	500–5000 µg mL^{-1}	56
Almond (*Prunus dulcis* cv. Casteltermini)	Seed skin	*n*-Hexane, ethanol	PP-rich	Maltose	Acarbose (50.1 ± 1.3 µg mL^{-1})	57.1 ± 2.6 µg DW mL^{-1}	NS	58
Almond (*Prunus amygdalus* Stokes)	Seed[c]	Water	NS	Maltose	Acarbose (NS)	46% at 100 000 µg DW mL^{-1} [a]	Single screen at 100 000 µg DW mL^{-1}	55
Chinese nutmeg yew (*Torreya grandis*)	Seed[c]	Ethanol 10% Ethanol 30% Ethanol 50% Ethanol 70%	PP-rich	*p*-Nitrophenyl-α-D-glucopyranoside	Acarbose (760 ± 10 µg mL^{-1})	ND 63 450 ± 2110 µg DW mL^{-1} 62 550 ± 750 µg DW mL^{-1} 600 ± 30 µg DW mL^{-1} 20 ± 00 µg DW mL^{-1} [j] 100 ± 10 µg DW mL^{-1} [k] 4650 ± 300 µg DW mL^{-1} [l] 5680 ± 810 µg DW mL^{-1} [m] 430 ± 20 µg DW mL^{-1} [n] 2250 ± 310 µg DW mL^{-1}	780–50 000 µg DW mL^{-1}	65
		Ethanol 90%						

Table 2 (Contd.)

| Nut | | Extraction | | Yeast enzyme assay | | Sample IC$_{50}$ or inhibition (%) | Samples concentration range tested | Ref. |
Name	Part	Conditions	Target	Substrate	Positive control (IC$_{50}$ or inhibition (%))			
Terebinth (*Pistacia terebinthus*)	Seed with skin	Hexane Acetone Ethanol	PP-rich	*p*-Nitrophenyl-α-D-glucopyranoside	Acarbose (10 300 µg mL⁻¹)	1580 µg DW mL⁻¹ 720 µg DW mL⁻¹ 1100 µg DW mL⁻¹	125–2000 µg DW mL⁻¹ 100–1000 µg DW mL⁻¹	54
Pistachio (*Pistacia vera* L.) Aegina cultivar Avdat cultivar Kastel cultivar Kerman cultivar Larnaka cultivar Mateur cultivar Napolitana cultivar Sirora cultivar	Seed[c]	Methanol, ascorbic acid, hexane	PP-rich	*p*-Nitrophenyl-α-D-glucopyranoside	NS	<50 µg of DW mL⁻¹ 2490 µg of DW mL⁻¹ 5940 µg of DW mL⁻¹ <50 µg of DW mL⁻¹ <50 µg of DW mL⁻¹ <50 µg of DW mL⁻¹ 3670 µg of DW mL⁻¹ 3690 µg of DW mL⁻¹[o]	NS	60
Marula nuts (*Sclerocarya birrea*)	Shelled seed	Methanol	PP-rich	*p*-Nitrophenyl-α-D-glucopyranoside	NS	7800 µg DW mL⁻¹[o]	NS	59
Heckel (*Ricinodendron heudelotii* (Baill.))	Seed[c]	Ethyl acetate Methanol Water	PP-rich	*p*-Nitrophenyl-α-D-glucopyranoside	Acarbose (NS)	1.3 ± 0.0 mmol acarbose equivalent per g of extract 1.3 ± 0.0 mmol acarbose equivalent per g of extract ND	NS	66
Manchurian walnut (*J. mandshurica* Maxim.)	Hydrolysed walnut peptides[c]	"Alcalase" alkaline protease hydrolysis and ultrafiltration	Purified peptides	*p*-Nitrophenyl-α-D-glucopyranoside	Acarbose (100% at 100 000 µg mL⁻¹)[a]	56.2 ± 1.6% at 60 000 µg mL⁻¹ (>10 kDa)[a] 61.7 ± 1.9% at 100 000 µg mL⁻¹ (3–10 kDa)[a] 46.6 ± 11.2% at 100 000 µg mL⁻¹ (<3 kDa)[a]	1000–100 000 µg DW mL⁻¹	63
Manchurian walnut (*J. mandshurica* Maxim.)	Fractionated and purified hydrolysed peptides[c]	"Alcalase" alkaline protease hydrolysis and ultrafiltration and chromatography	Purified peptides	*p*-Nitrophenyl-α-D-glucopyranoside	Acarbose (73% at 2000 µM)[a]	41.6% at 2000 µg mL⁻¹[a,p] 33.7% at 2000 µg mL⁻¹[a,q] 50.1% at 2000 µM[r]	100–2000 µg mL⁻¹ 100–2000 µM	64
Siberian apricot (almond) (*Armeniaca sibirica*)	Almond oil manufacture residue[c]	Defatted protein extract enzymatically hydrolysed by "Prote Ax" or "Protease M"; ultrafiltered	Purified peptides	*p*-Nitrophenyl-α-D-glucopyranoside	NS	2080 ± 10 µg mL⁻¹[s] 97 ± 4 µg mL⁻¹[t] 7.4 ± 0.3 µg mL⁻¹[u] 0.58 ± 0.02 µg mL⁻¹[v] 380 ± 20 µg mL⁻¹[w] 45 ± 3 µg mL⁻¹[x] 19 ± 1 µg mL⁻¹[y] 13 ± 6 µg mL⁻¹[z]	NS	57

Data are expressed as mean (± standard deviation where specified). Abbreviations: ND, no inhibition detected; NS, not specified; DW, dry weight; PP, polyphenol. [a] No information on IC$_{50}$. [b] No information on the lowest concentration tested. [c] No further details (*e.g.* no details on part of nut used, no mention of skin left on seed or not, or identification of compounds present). [d] Inhibition value of the Chilean hazelnut (*Gevuina avellana*), collected from Region del Bio-Bio (Contulmo) in May of 2016 and callana roasted, was not determined due to the low amount of material. [e] Chilean hazelnut (*Gevuina avellana*) from Region del Maule. [f] Chilean hazelnut (*Gevuina avellana*) from Region del Bio-Bio. [g] Chilean hazelnut (*Gevuina avellana*), from Region de Nuble. [h] Chilean hazelnut (*Gevuina avellana*) from Yungay, Region de Nuble. [i] Chilean hazelnut (*Gevuina avellana*) from Region del Bio-Bio. [j] Chilean hazelnut (*Gevuina avellana*) from Region de Los Lagos. [j] Dichloromethane fraction. [k] Ethyl acetate fraction. [l] *N*-Butanol fraction. [m] Aqueous residue. [n] Crude extract, dissolved dried extract with water and lyophilized then dissolved with 70% ethanol. [o] Estimated from figure in the paper and not actually stated. [p] "A2" fraction which was the most potent fraction after purification of 3–10 kDa walnut protein hydrolysates by gel filtration chromatography (Sephadex G-25 column) and RP-HPLC (reverse phase high-performance liquid chromatography). [q] "B1" which is further purification of A2 on a Sephadex G-15 column. [r] "LPLLR is a novel pentapeptide, identified in fraction C1 after further purification of B1 by RP-HPLC. [s] Hydrolysates from Prote Ax (Trp-His), 0–5 kDa fraction. [t] 0–5 kDa fraction was purified (by gel filtration chromatography on a Sephadex G-25 column) into three subfractions, of which one (P3) exhibited the highest inhibitory activity. [u] Hydrolysates from Prote Ax, the P3 subfraction was collected and further purified by RP-HPLC (peptide A). [w] Hydrolysates from Protease M (Trp-Ser), 0–5 kDa fraction. [v] P3P2 was further purified by molecular sieve and a single peptide was purified (by gel filtration chromatography on a Sephadex G25 column) into three subfractions, of which this one (P3P2) had the highest inhibitory activity. [y] Hydrolysates from Protease M (Trp-His), 0–5 kDa fraction. [x] 0–5 kDa fraction was purified (by gel filtration chromatography on a Sephadex G25 column) into seven subfractions, of which P2P2 had the highest inhibitory activity. [z] P2P2 was further purified by molecular sieve and a single peptide was collected and further purified by RP-HPLC (peptide B).

Table 3 Comparison of inhibition of rat and yeast α-glucosidase activity by nut extracts

Nut	Part of nut	Extract type	Substrate	Positive control (IC$_{50}$)	Samples IC$_{50}$ (yeast enzyme)	Sample IC$_{50}$ (rat enzyme)	Ref.
Chilean hazelnut (*Gevuina avellana*), raw[a] Chilean hazelnut (*Gevuina avellana*), roasted[b]	Seed[a]	PP-rich	*p*-Nitrophenyl-α-D-glucopyranoside	Acarbose (120.9 ± 2.0 µg mL^{-1})	21.1 ± 14.6 µg DW mL^{-1a} 33.4 ± 32.2 µg DW mL^{-1b}	—	61
Hazelnut (*Corylus avellana L.*)	Meal[c]	Purified peptides	*p*-Nitrophenyl-α-D-glucopyranoside	NS	—	3755 ± 191 µg DW mL^{-1d}	17
Almond (*Armeniaca sibirica syn. Prunus sibirica*)	Seed skin	PP-rich	Maltose	Acarbose (50.1 ± 1.3 µg mL^{-1})	57.1 ± 2.6 µg DW mL^{-1}	—	58
Almond (*Prunus dulcis*)	Roasted seed skin	PP-rich	Maltose	NS	—	468 µg DW mL^{-1}	18
			Sucrose			627 µg DW mL^{-1}	

Data are expressed as mean (± standard deviation where specified) (*n* = 3). Abbreviations: ND, no inhibition detected; NS, not specified; DW, dry weight; PP, polyphenol. [a] Average of all raw samples from different regions (*n* = 2). [b] Average of all roasted samples from different regions (*n* = 13). [c] No further details. [d] Average of peptide fractions <5 kDa (*n* = 2).

compositional analysis (*e.g.*, phytochemical), of the test inhibitors used.[55,63] Two studies also failed to provide the nut origin/supplier,[17,55] while 40% of studies were lacking this information for other solvents and reagents used throughout the extraction process and/or enzyme assay, and three studies lacked details on the nut extraction method (*e.g.*, solvent, time and temperature).[55,60,63]

Surprisingly more than 66% of the studies did not provide details on the type or source of enzyme,[53,56–61,63,64,66] with some requiring a search through secondary or even tertiary citations to ascertain that the yeast enzyme had been used, and 5 of 15 studies did not provide the amount/concentration of enzyme that was used.[18,58,60,61,66] Almost half of the studies were lacking some or all details on the enzyme assay, including pH, buffer, incubation time and temperature, and concentration/amount of enzyme added; each of which affects enzyme activity and inhibition,[17,18,55,58,60,61,66] and in three studies, the method of detection or endpoint, used to calculate enzyme activity/inhibition, was not specified.[18,58,66]

More than 80% of studies did not provide information on the use of positive controls, negative controls and/or the concentration of any controls used, and more than half did not mention the concentration range that was tested to calculate the IC$_{50}$ value. All studies should have an inhibitor-free control in order to measure inhibition percentage or the IC$_{50}$ value, but most did not provide information on substrate-free or enzyme-free controls, and half did not specify the inhibition percentage or IC$_{50}$ value for the positive control.[17,18,53,56,57,59,60] The description of results for all endpoints investigated was not complete in most studies. For example, authors do not describe any evaluation of endogenous sugars in the test inhibitor substance, nor do they mention specific enzyme activities or provide data relating to the controls. The statistical methods for data analysis of all studies were given and applied transparently. According to the

chosen test system, enzyme assay parameters, number of doses and their range (for samples or controls), and/or inclusion of all the relevant results, all of the studies did not have an adequate and suitable study design to detect the anticipated effects. Further, the quantitative results of four of the studies are deemed not reliable due to a lack of presentation of data variability, an unusual way of calculating/presenting data, or a lack of clear dose dependent effects for putative inhibitors.[18,60,65,66]

Based on these assessments, we have developed a Quality Control Checklist for future studies on *in vitro* inhibition of enzyme activity (Table 4) which recommend future strategies to conduct and report data on inhibition of α-glucosidase activity.

4. Discussion

This review evaluates research investigating the inhibitory effects of extracts from edible parts of nuts on α-glucosidase activity. Although the main objective was to assess the literature on human α-glucosidase inhibition, no studies were found using this enzyme source. Results demonstrate that most extracts/compounds are stronger inhibitors of yeast α-glucosidase compared to mammalian (rat) α-glucosidases. Therefore, although extracts from nuts may inhibit yeast α-glucosidase, it is never clear whether these compounds can also inhibit human (or rat) α-glucosidase unless assays have been done.

4.1. Effect of nut extracts on yeast α-glucosidase

Nuts are sources of bioactive compounds including peptides and polyphenols.[33–35,61] Although data obtained from yeast α-glucosidase inhibition are irrelevant to human health and disease, findings of the current review show an inhibitory potential of nut extracts on yeast α-glucosidase, which may be

Food & Function

Table 4 Criteria of the data reliability assessment tool for *in vitro* carbohydrate digestive enzyme inhibition assays

No.	Criteria	Explanations
Criteria group I: test substance identification		
1	Is the test substance identified?	Information on components and composition is expected. For plant extracts (*e.g.* nuts, fruits), details about the plant part used (*e.g.* fruit, seed, with/without skin) and processing applied (*e.g.* shelling, grinding, roasting, juicing) is expected
2	Is the concentration and purity of the test substance given?	Quantitative and qualitative information on the test substance purity and associated analyses are expected, including: - Names and amounts of bioactive compounds (*e.g.* specific polyphenol or peptide) and/or the total amount of bioactive compounds (*e.g.* total amount of polyphenols) present in the test substance - Type of analytical technique used to assess composition (*e.g.* LC-MS, Folin–Ciocalteu assay) - Names, grades, concentrations and volumes of solvents, enzymes and reagents used during purity assay - Relevant details of the purity assay, including buffer, pH, incubation time and temperature *etc.* provided, if applicable - Standards, including concentration range, where required (*e.g.* EGCG for Folin assay)
3	Is information on the source of all substances given?	a. Source/origin and supplier of the main test substance(s) is essential b. Source/supplier of all other chemicals is expected (*e.g.* enzyme assay substrate, enzyme, reagents, solvents, buffer, *etc.*)
4	Is all information on the preparation of the test substance given?	Method(s) used to extract/prepare samples, including details on solvents, times, temperatures, buffers, pH, *etc.*, and tests used to determine yield/quality of extract (see criterion 2 for required information) must be given, unless no such additional information is needed
Criteria group II: test system characterisation		
5	Is the enzyme assay well described?	Essential information about the enzyme assay includes: - Volume and concentration of substrate - Volume, concentration and pH of buffer - Incubation time and temperature - How the enzyme reaction was stopped
6	Is information given on the source/origin of the enzyme?	It is absolutely vital that details on the specific enzyme (ideally EC number) used, and the species from which it was sourced, are included with any published *in vitro* enzyme assay data. The enzyme may be commercially available or extracted from cultured cells, tissues or biospecimens, *etc.* If commercial, supplier details must be provided (see criterion 3b); if extracted by the researchers, details on the extraction process must be provided
7	Is necessary information on test system properties and conditions given?	Necessary information on the test system includes: a. Amount/concentration of enzyme (confirmed by measuring specific activity with no test inhibitors present and providing this value) b. Concentrations of positive (and negative if applicable) controls (*e.g.* acarbose)
Criteria group III: study design description		
8	Is the test substance concentration range given?	IC_{50} values without information on the concentrations investigated in the assays are not considered sufficient
9	Are observation time-points explained?	This will typically apply to the time of the endpoint measurement at the end of the assay. Time points of further observations (*e.g.* kinetic assays) may not be mentioned when the experimental set-up makes clear that observation takes place immediately after end of assay (considered sufficient). Please also check figures and tables for respective information
10	Were negative controls included?	Negative controls are required for all *in vitro* studies. Not only an inhibitor-free control, since all studies must have used one to obtain IC_{50} or inhibition% values, but substrate-free and enzyme-free controls must have been used as well, with details provided
11	Were positive controls included?	Positive controls which are known inhibitors (*e.g.* acarbose) are required for all *in vitro* enzyme assays to confirm the test system is working as expected
12	Is the number of replicates (and complete repetitions of the experiment) given?	It is expected that assays are completed a minimum of three times, ideally on three separate days and, where enzymes are extracted from cells, tissues, animals or participants, the assay must be performed using enzymes from at least three biological replicates, with all relevant information on replicates provided
Criteria group IV: study results documentation		
13	Are the study endpoint(s) and their method(s) of determination clearly described?	A description of how enzyme activity/inhibition was measured. This may be indirectly by using colorimetric methods with reducing sugars and dinitrosalicylic acid (DNSA) or chromophore-linked substrates (*e.g. p*-nitrophenyl-α-D-glucopyranoside) or directly by chromatography

Table 4 *(Contd.)*

No.	Criteria	Explanations
14	Is the description of the study results for all endpoints investigated transparent and complete?	Results on all study endpoints described in the Methods section should be provided. Study results include specific enzyme activity, inhibition at each individual concentration investigated, results for positive and all negative controls, and other relevant details (*e.g.* when testing an extract, an enzyme-free control is necessary to check that the extract did not contain any endogenous sugars and/or enzymatic activity). Check figures and tables for relevant information
15	Are the statistical analyses given and applied transparently?	No in-depth examination and/or recalculation is expected here; rather the criterion asks for proper documentation. Only judge reported information. Where statistics are lacking, but considered indispensable, please consider this under "Plausibility of study design", below
Criteria group V: plausibility of study design and results		
16	Is the chosen study design appropriate for obtaining the substance-specific data aimed for?	Is the study design adequate and suitable to detect the anticipated effects in the test system used? Please don't give points if study design contains substantial flaws! Critical issues may be: - The chosen test system and its applicability domain - Number of replicates, number of concentrations/dose levels and their range and spread - Lack of negative control - Inclusion of all relevant endpoints - Lack of statistical evaluation - Source/type of enzyme - Concentration and amount of enzyme - How enzyme activity is measured
17	Are the quantitative study results reliable?	Please give points, such as if there are reasons to trust or mistrust the numerical values. Arguments here may be: - Was the observed variability of results, as well as that of negative/positive controls, acceptable? - Were control values in a reasonable range? Considerations will differ depending on the study type. Inherent high variability of a biological system should not be a reason to refuse making the point

We report a modification of the ToxRTool[52] to enable assessment of the quality of *in vitro* enzyme assays and act as a guide for researchers undertaking these types of experiment and publishing such data.

attributed to the polyphenol content[7,12,44] or peptides.[57,64] Compared to acarbose, Chinese nutmeg yew, Chilean hazelnut and Terebinth showed 38-fold, 33-fold, and 14-fold higher inhibition values, respectively. Also, almond, Pistachio, Marula nuts, and Heckel all show inhibition of yeast α-glucosidase. The findings of the present study are in line with the literature which has indicated that polyphenols and bioactive peptides may inhibit α-glucosidase.[7,12,68,69] It is worth noting, however, that nut extraction and enzyme assay methods varied vastly between the studies, so differences in inhibitory potential may be due to experimental approach, rather than differences between the nuts and nut composition.

4.2 Differences between yeast and mammalian α-glucosidase

Table 5 presents the inhibition values of some other extracts and compounds for yeast and mammalian α-glucosidase activity, which serves to demonstrate the vast differences in the inhibitory activity against different sources of α-glucosidases. Four types of medical plant, including *Peltophorum africanum*, *Manilkara mochisia*, *Ozoroa cf. albicans*, and *Cassia abbreviate*, were 50-fold to 250-fold stronger inhibitors of yeast α-glucosidase compared to rat α-glucosidase.[70] However, acarbose is a better inhibitor of human or rat α-glucosidases compared to the yeast enzyme. According to Table 5, all polyphe-

nols, except quercetagetin, showed better inhibition of yeast α-glucosidase. The IC$_{50}$ for quercetagetin was >8-fold lower for human sucrase activity than that of yeast, while the inhibition values for quercetin against human sucrase and yeast α-glucosidase were similar.[11,71,72] A stark difference is seen for cyanidin, with almost complete inhibition of the yeast enzyme at just 4 μM, whereas the rat enzyme was not inhibited at all.[48] Thus yeast and mammalian α-glucosidases have shown very different inhibition potentials.[10,70,73] In agreement with the results of the present review, Babu *et al.*,[10] observed that the methanolic extract of Himalayan rhubarb is a better inhibitor of yeast α-glucosidase than the equivalent amount of mammalian α-glucosidase. A study of various foods extracts (extracts such as green tea, chicken essence, and yogurt were used to identify the effect of naturally-occurring food components on rat and yeast α-glucosidase activity) inhibited yeast α-glucosidase whereas no inhibition was found on rat α-glucosidase.[74] These differences between rat and yeast α-glucosidase inhibition are related to molecular structural differences.[10,70] It has been noted that yeast and mammalian α-glucosidase are enzymically totally different and distinct. Yeast α-glucosidase is a 584 amino acid soluble protein of glycosyl hydrolase family 13, whereas human sucrase/isomaltase, for example, is a complex membrane-associated protein of

Table 5 Comparison of inhibition of yeast and mammalian α-glucosidase activity by other compounds and extracts

Inhibitor	IC$_{50}$ or inhibition (%) of yeast enzyme	IC$_{50}$ or inhibition (%) of human (or rat where stated) enzyme		Ref.
Acarbose	IC$_{50}$ 2300 μM	Isomaltose	IC$_{50}$ 39.1 ± 2.1 μM	11, 12 and 70
		Sucrase	IC$_{50}$ 1.7 ± 0.3 μM	
			IC$_{50}$ 12.3 ± 0.6 μM (rat)	
		Maltase	IC$_{50}$ 13.9 ± 2.3 μM	
			IC$_{50}$ 0.42 ± 0.02 μM (rat)	
		IC$_{50}$ 619.6 μM (rat)		
Peltophorum africanum	IC$_{50}$ 40 μg mL^{-1}	IC$_{50}$ > 2500 μg mL^{-1} (rat)		70
Manilkara mochisia	IC$_{50}$ 50 μg mL^{-1}	IC$_{50}$ > 2500 μg mL^{-1} (rat)		
Ozoroa cf. albicans	IC$_{50}$ 50 μg mL^{-1}	IC$_{50}$ > 2500 μg mL^{-1} (rat)		
Cassia abbreviata	IC$_{50}$ 10 μg mL^{-1}	IC$_{50}$ > 2500 μg mL^{-1} (rat)		
Apigenin	43% at >200 μM	3% at >500 μM (rat)		48
Cyanidin	99% at 4 μM	6% at >500 μM (rat)		
EGCG	IC$_{50}$ 0.99 ± 0.07 μM	Isomaltose	IC$_{50}$ 461.9 ± 60.3 μM	11, 12 and 75
		Sucrase	IC$_{50}$ 175.2 ± 60.1 μM	
			IC$_{50}$ 950 ± 86 μM (rat)	
		Maltase	IC$_{50}$ 186.4 ± 40.4 μM	
			IC$_{50}$ 14.0 ± 2.0 μM (rat)	
Quercetin	IC$_{50}$ 163.4 ± 3.4 μM	Sucrase	IC$_{50}$ 161.9 ± 13.6 μM	11, 71 and 72
			IC$_{50}$ 364.0 μM (rat)	
		Maltase	IC$_{50}$ 247.3 ± 7.0 μM	
			IC$_{50}$ 231.6 μM (rat)	
Quercetagetin	IC$_{50}$ 180.1 ± 3.7 μM	Sucrase	IC$_{50}$ 21.7 ± 5.3 μM	
Gallic acid	IC$_{50}$ 143.4 ± 4.1 μM	Sucrase	IC$_{50}$ 1757.6 ± 19.3 μM (rat)	83
		Maltase	IC$_{50}$ 710.6 ± 12.3 μM (rat)	
(−)-Epicatechin	24% at >200 μM	Sucrase	IC$_{50}$ 1080 μM (rat)	48 and 84
		Maltase	IC$_{50}$ 770 μM (rat)	
(−)-Epigallocatechin	IC$_{50}$ 75 μM	Sucrase	IC$_{50}$ 921 μM (rat)	
		Maltase	IC$_{50}$ 1260 μM (rat)	
(−)-Epigallocatechin-3-O-gallate	89% at 2 μM	Sucrase	IC$_{50}$ 169 μM (rat)	
		Maltase	IC$_{50}$ 40 μM (rat)	

Data are expressed as mean (± standard deviation where specified).

1827 amino acids of glycoside hydrolase family 1. In addition, type I (yeast) and II (mammals) enzymes even have different amino acids in their catalytic sites.[73]

4.3. Differences between rat and human α-glucosidase

The inhibition of human sucrase activity by acarbose is greater than on rat sucrase, whereas rat maltase activity is more susceptible to inhibition by acarbose compared to human maltase.[12] The same pattern can be seen for human and rat α-glucosidase inhibition by EGCG and quercetin[11,12,71,75] (Table 5). Although there are some similarities between rat and human α-glucosidase, the 74% homology in sucrase-isomaltase is sufficient to give rise to different specificities of inhibition;[76] therefore, it can be concluded that even the inhibitory effect of different compounds/extracts on rat and human α-glucosidase are not equivalent. One reason for this mismatch is that N-glycosylation, which can affect inhibition due to steric hindrance, is different in rat and human sucrase-isomaltase.[76] The human and rat sequences contain 18 and 16 N-glycosylation sites, respectively, while only 9 of them are in the same positions[76] (Fig. 2).

4.4. Limitations

There were a number of limitations in this review. The most important point to note is that there were no studies on the inhibitory effect of extracts from edible parts of nuts on human α-glucosidase and the vast majority of studies in this area used the yeast enzyme. Another significant point is that all the studies in this review estimated α-glucosidase activity indirectly by using colorimetric methods such as reducing sugars/dinitrosalicylic acid (DNSA) or chromophore-linked substrates. In most of the colorimetric methods, coloured compounds such as phenolics can directly interfere with the method and contribute to the endpoint absorbance determination.[6,77,78] The DNSA reagent is used to measure the reducing ability of the sugar product and so estimate carbohydrate hydrolysis. Therefore, endogenous sugars of plant extracts can affect the reducing sugars method for enzyme activity.[6] Additionally, it has been reported that in reaction mixtures containing peptides the measurement was overestimated when using DNSA.[79] No study in this review has used direct chromatography, which is the most precise method to measure enzyme activity.[77] Lack of consistency in reporting enzyme amount, plus using enzymes from different sources, of different types (*e.g.*, sucrase or maltase), and from different suppliers which will have different activities, highlights the need to present control (*i.e.* inhibitor-free or substrate-free) data and the specific enzyme activity. Most studies did not mention information on negative controls, including enzyme-free control or substrate-free control, while it is crucial to

Fig. 2 Primary structure of human and rat sucrase-isomaltase. The black region is the N-terminal non-cleavable signal sequence, which in addition serves as the transmembrane sequence. The grey region which is the highly *O*-glycosylated region can be found in each isomaltase sequence. The light blue and dark blue regions are low- and high-homology regions, respectively, between the corresponding regions of sucrase-isomaltase from these species. Created with BioRender.com.

measure the amount of endogenous sugars in inhibitor samples and the effect of enzyme on inhibitors without substrate. Some studies lacked details about pH, temperature, or the buffer used for the enzyme assay, all of which can affect enzyme activity and inhibition.[77,80] Within the reviewed studies, there are limitations regarding nut preparation. Some papers did not specify the details of the extracted part of the nuts (*e.g.* removing the skin) and studies in this review lack consistency in the nut extraction method used. For example, the nut extraction solvents varied across studies and may have influenced the effectiveness of enzyme inhibition due to affecting the availability and activity of bioactive compounds within the nut extracts.[81,82] Further, the studies lack consistency in the concentration units and amount or type of substrate for measuring IC$_{50}$ values. Hence, the comparison between studies is not meaningful. Also, the absence of acarbose as a positive control in eight studies complicates the comparison between various nut extracts.[53,55–57,59,60,66] Due to the small number of included studies for rat enzyme inhibition, it is difficult to determine whether compounds in nut extracts are effective inhibitors of mammalian α-glucosidase.

These limitations, coupled with the lack of studies on human α-glucosidase, and growing attention to nuts as an important component of a healthy diet with potential to reduce T2DM risk,[16] highlight the need for future research to evaluate the inhibitory effect of extracts from nuts on human α-glucosidase activities.

5. Conclusion

Among extensive research which has been done on nuts and health outcomes, none has investigated the inhibitory effects of extracts from edible nuts on human α-glucosidase activities and most of the studies have been conducted on the yeast α-glucosidase. The yeast α-glucosidase is poorly inhibited by acarbose, a positive control which is used clinically since it is highly effective at inhibiting human α-glucosidase activities, but acarbose is always a stronger inhibitor of the mammalian α-glucosidase compared to the yeast enzyme. In order to be relevant to human health and disease, future work must utilise human, or at least mammalian, α-glucosidase enzyme sources.

Abbreviations

T2DM	Type 2 diabetes mellitus
INPLASY	International Platform of Registered Systematic Review and Meta-analysis Protocols
PRISMA	Preferred Reporting Items for Systematic reviews and Meta-Analyses
RP-HPLC	Reverse phase high performance liquid chromatography
DNSA	Dinitrosalicylic acid

Author contributions

GW developed the concept and supervised the research. Data were extracted independently by MF and MM and verified by MJH. MF and MJH developed the quality assessment tool. MF wrote the first version of the manuscript and MM, MJH and GW edited the manuscript. All the authors contributed to the writing of the manuscript and approved the final version.

Conflicts of interest

The authors report no current relevant conflict of interest.

Acknowledgements

References

1 O. O. Oguntibeju, Type 2 diabetes mellitus, oxidative stress and inflammation: examining the links, *Int. J. Physiol., Pathophysiol. Pharmacol.*, 2019, **11**, 45–63.

2 S. N. Bhupathiraju, D. K. Tobias, V. S. Malik, A. Pan, A. Hruby, J. E. Manson, W. C. Willett and F. B. Hu, Glycemic index, glycemic load, and risk of type 2 diabetes: results from 3 large US cohorts and an updated meta-analysis, *Am. J. Clin. Nutr.*, 2014, **100**, 218–232.

3 K. Marsh, A. Barclay, S. Colagiuri and J. Brand-Miller, Glycemic index and glycemic load of carbohydrates in the diabetes diet, *Curr. Diabetes Rep.*, 2011, **11**, 120–127.

4 A. D. Baron, Postprandial hyperglycaemia and α-glucosidase inhibitors, *Diabetes Res. Clin. Pract.*, 1998, **40**, S51–S55.

5 H. Nyambe-Silavwe and G. Williamson, Polyphenol- and fibre-rich dried fruits with green tea attenuate starch-derived postprandial blood glucose and insulin: a randomised, controlled, single-blind, cross-over intervention, *Br. J. Nutr.*, 2016, **116**, 443–450.

6 R. Visvanathan, M. Qader, C. Jayathilake, B. C. Jayawardana, R. Liyanage and R. Sivakanesan, Critical review on conventional spectroscopic α-amylase activity detection methods: merits, demerits, and future prospects, *J. Sci. Food Agric.*, 2020, **100**, 2836–2847.

7 G. Williamson, Possible effects of dietary polyphenols on sugar absorption and digestion, *Mol. Nutr. Food Res.*, 2013, **57**, 48–57.

8 J. A. Balfour and D. McTavish, Acarbose, *Drugs*, 1993, **46**, 1025–1054.

9 K. Y. Loo, K. H. Leong, Y. Sivasothy, H. Ibrahim and K. Awang, Molecular insight and mode of inhibition of α–glucosidase and α–amylase by Pahangensin A from Alpinia pahangensis Ridl, *Chem. Biodivers.*, 2019, **16**, e1900032–e1900039.

10 K. S. Babu, A. K. Tiwari, P. V. Srinivas, A. Z. Ali, B. C. Raju and J. M. Rao, Yeast and mammalian α-glucosidase inhibitory constituents from Himalayan rhubarb Rheum emodi Wall. ex Meisson, *Bioorg. Med. Chem. Lett.*, 2004, **14**, 3841–3845.

11 E. Barber, M. J. Houghton and G. Williamson, Flavonoids as human intestinal α-glucosidase inhibitors, *Foods*, 2021, **10**, 1939–1960.

12 A. Pyner, H. Nyambe-Silavwe and G. Williamson, Inhibition of human and rat sucrase and maltase activities to assess antiglycemic potential: Optimization of the assay using acarbose and polyphenols, *J. Agric. Food Chem.*, 2017, **65**, 8643–8651.

13 B. Dalile, C. Kim, A. Challinor, L. Geurts, E. R. Gibney, M. V. Galdos, G. La Fata, S. Layé, J. C. Mathers and D. Vauzour, The EAT–Lancet reference diet and cognitive function across the life course, *Lancet Planet. Health*, 2022, **6**, e749–e759.

14 E. H. Haddad, J. Sabate and C. G. Whitten, Vegetarian food guide pyramid: a conceptual framework, *Am. J. Clin. Nutr.*, 1999, **70**, 615s–619s.

15 R. K. Johnson and E. Kennedy, The 2000 dietary guidelines for americans: what are the changes and why were they made?, *J. Acad. Nutr. Diet.*, 2000, **100**, 769–774.

16 J. C. Lovejoy, The impact of nuts on diabetes and diabetes risk, *Curr. Diabetes Rep.*, 2005, **5**, 379–384.

17 S. Simsek, Angiotensin I-converting enzyme, dipeptidyl peptidase-IV, and α-glucosidase inhibitory potential of hazelnut meal protein hydrolysates, *J. Food Meas. Charact.*, 2021, **15**, 4490–4496.

18 T. Tsujita, T. Shintani and H. Sato, α-Amylase inhibitory activity from nut seed skin polyphenols. 1. Purification and characterization of almond seed skin polyphenols, *J. Agric. Food Chem.*, 2013, **61**, 4570–4576.

19 C. Luo, Y. Zhang, Y. Ding, Z. Shan, S. Chen, M. Yu, F. B. Hu and L. Liu, Nut consumption and risk of type 2 diabetes, cardiovascular disease, and all-cause mortality: a systematic review and meta-analysis, *Am. J. Clin. Nutr.*, 2014, **100**, 256–269.

20 L. C. Del Gobbo, M. C. Falk, R. Feldman, K. Lewis and D. Mozaffarian, Effects of tree nuts on blood lipids, apolipoproteins, and blood pressure: systematic review, meta-analysis, and dose-response of 61 controlled intervention trials, *Am. J. Clin. Nutr.*, 2015, **102**, 1347–1356.

21 K. Jaceldo-Siegl, E. Haddad, K. Oda, G. E. Fraser and J. Sabaté, Tree nuts are inversely associated with metabolic syndrome and obesity: the Adventist health study-2, *PLoS One*, 2014, **9**, e85133.

22 R. Jiang, J. E. Manson, M. J. Stampfer, S. Liu, W. C. Willett and F. B. Hu, Nut and peanut butter consumption and risk of type 2 diabetes in women, *J. Am. Med. Assoc.*, 2002, **288**, 2554–2560.

23 G. Asghari, Z. Ghorbani, P. Mirmiran and F. Azizi, Nut consumption is associated with lower incidence of type 2 diabetes: The Tehran Lipid and Glucose Study, *Diabetes Metab.*, 2017, **43**, 18–24.

24 J. Kochar, J. M. Gaziano and L. Djoussé, Nut consumption and risk of type II diabetes in the Physicians' Health Study, *Eur. J. Clin. Nutr.*, 2010, **64**, 75–79.

25 A. Afshin, R. Micha, S. Khatibzadeh and D. Mozaffarian, Consumption of nuts and legumes and risk of incident ischemic heart disease, stroke, and diabetes: a systematic review and meta-analysis, *Am. J. Clin. Nutr.*, 2014, **100**, 278–288.

26 D. Aune, N. Keum, E. Giovannucci, L. T. Fadnes, P. Boffetta, D. C. Greenwood, S. Tonstad, L. J. Vatten, E. Riboli and T. Norat, Nut consumption and risk of cardiovascular disease, total cancer, all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis of prospective studies, *BMC Med.*, 2016, **14**, 207.

27 E. Ros, Health benefits of nut consumption, *Nutrients*, 2010, **2**, 652–682.

28 P. Hernández-Alonso, L. Camacho-Barcia, M. Bulló and J. Salas-Salvadó, Nuts and dried fruits: An update of their beneficial effects on type 2 diabetes, *Nutrients*, 2017, **9**, 673.

29 G. Brufau, J. Boatella and M. Rafecas, Nuts: source of energy and macronutrients, *Br. J. Nutr.*, 2006, **96**(Suppl 2), S24–S28.

30 R. Segura, C. Javierre, M. A. Lizarraga and E. Ros, Other relevant components of nuts: phytosterols, folate and minerals, *Br. J. Nutr.*, 2006, **96**(Suppl 2), S36–S44.

31 A. Wojdyło, I. P. Turkiewicz, K. Tkacz, P. Nowicka and Ł. Bobak, Nuts as functional foods: Variation of nutritional and phytochemical profiles and their in vitro bioactive properties, *Food Chem.: X*, 2022, **15**, 100418.

32 R. Blomhoff, M. H. Carlsen, L. F. Andersen and D. R. Jacobs Jr., Health benefits of nuts: potential role of antioxidants, *Br. J. Nutr.*, 2006, **96**(Suppl 2), S52–S60.

33 Y. Kim, J. B. Keogh and P. M. Clifton, Benefits of nut consumption on insulin resistance and cardiovascular risk factors: Multiple potential mechanisms of actions, *Nutrients*, 2017, **9**, 1271–1310.

34 M. Kornsteiner, K.-H. Wagner and I. Elmadfa, Tocopherols and total phenolics in 10 different nut types, *Food Chem.*, 2006, **98**, 381–387.

35 Y. Liu, J. B. Blumberg and C.-Y. O. Chen, Quantification and bioaccessibility of California pistachio bioactives, *J. Agric. Food Chem.*, 2014, **62**, 1550–1556.

36 L. L. P. Ramos, F. Jiménez-Aspee, C. Theoduloz, A. Burgos-Edwards, R. Domínguez-Perles, C. Oger, T. Durand, Á. Gil-Izquierdo, L. Bustamante and C. Mardones, Phenolic, oxylipin and fatty acid profiles of the Chilean hazelnut (Gevuina avellana): Antioxidant activity and inhibition of pro-inflammatory and metabolic syndrome-associated enzymes, *Food Chem.*, 2019, **298**, 125026–125039.

37 G. Cirillo, M. Curcio, O. Vittorio, F. Iemma, D. Restuccia, U. G. Spizzirri, F. Puoci and N. Picci, Polyphenol conjugates and human health: a perspective review, *Crit. Rev. Food Sci. Nutr.*, 2016, **56**, 326–337.

38 T. Y. Forbes-Hernandez, M. Gasparrini, S. Afrin, S. Bompadre, B. Mezzetti, J. L. Quiles, F. Giampieri and M. Battino, The healthy effects of strawberry polyphenols: which strategy behind antioxidant capacity?, *Crit. Rev. Food Sci. Nutr.*, 2016, **56**, S46–S59.

39 Y. Ma, Y. Shang, D. Zhu, C. Wang, Z. Zhong and Z. Xu, Facile separation of 5-O-galloylquinic acid from chinese green tea extract using mesoporous zirconium phosphate, *Phytochem. Anal.*, 2016, **27**, 153–157.

40 M. Maldini, M. Chessa, G. L. Petretto, P. Montoro, J. P. Rourke, M. Foddai, M. Nicoletti and G. Pintore, Profiling and simultaneous quantitative determination of anthocyanins in wild Myrtus communis L. berries from different geographical areas in sardinia and their comparative evaluation, *Phytochem. Anal.*, 2016, **27**, 249–256.

41 S. A. Palma-Duran, A. Vlassopoulos, M. Lean, L. Govan and E. Combet, Nutritional intervention and impact of polyphenol on glycohemoglobin (HbA1c) in non-diabetic and type

2 diabetic subjects: Systematic review and meta-analysis, *Crit. Rev. Food Sci. Nutr.*, 2017, **57**, 975–986.

42 L.-W. Qi, E.-H. Liu, C. Chu, Y.-B. Peng, H.-X. Cai and P. Li, Anti-diabetic agents from natural products—an update from 2004 to 2009, *Curr. Top. Med. Chem.*, 2010, **10**, 434–457.

43 C. Aneklaphakij, T. Saigo, M. Watanabe, T. Naake, A. R. Fernie, S. Bunsupa, V. Satitpatipan and T. Tohge, Diversity of chemical structures and biosynthesis of polyphenols in uut-bearing species, *Front. Plant Sci.*, 2021, **12**, 642581–642595.

44 J. Xiao, G. Kai, K. Yamamoto and X. Chen, Advance in dietary polyphenols as α-glucosidases inhibitors: a review on structure-activity relationship aspect, *Crit. Rev. Food Sci. Nutr.*, 2013, **53**, 818–836.

45 X. Peng, G. Zhang, Y. Liao and D. Gong, Inhibitory kinetics and mechanism of kaempferol on α-glucosidase, *Food Chem.*, 2016, **190**, 207–215.

46 P. K. Mujawdiya and S. Kapur, Screening of antioxidant and α-glucosidase inhibitory activities of Indian medicinal plants, *Curr. Enzyme Inhib.*, 2020, **16**, 145–154.

47 T. Bansode and B. Salalkar, Strategies in the Design of Antidiabetic Drugs from Terminalia Chebula Retz. Using in silico and in vitro Approach, *MicroMedicine*, 2016, **4**, 60–67.

48 K. Tadera, Y. Minami, K. Takamatsu and T. Matsuoka, Inhibition of alpha-glucosidase and alpha-amylase by flavonoids, *J. Nutr. Sci. Vitaminol.*, 2006, **52**, 149–153.

49 E. Lo Piparo, H. Scheib, N. Frei, G. Williamson, M. Grigorov and C. J. Chou, Flavonoids for controlling starch digestion: structural requirements for inhibiting human alpha-amylase, *J. Med. Chem.*, 2008, **51**, 3555–3561.

50 D. R. Rose, M. M. Chaudet and K. Jones, Structural studies of the intestinal α-glucosidases, maltase-glucoamylase and sucrase-isomaltase, *J. Pediatr. Gastroenterol. Nutr.*, 2018, **66**, S11–S13.

51 D. Moher, A. Liberati, J. Tetzlaff and D. G. Altman, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, *Ann. Intern. Med.*, 2009, **151**, 264–269.

52 K. Schneider, M. Schwarz, I. Burkholder, A. Kopp-Schneider, L. Edler, A. Kinsner-Ovaskainen, T. Hartung and S. Hoffmann, "ToxRTool", a new tool to assess the reliability of toxicological data, *Toxicol. Lett.*, 2009, **189**, 138–144.

53 S. A. Adefegha, G. Oboh, S. I. Oyeleye and I. Ejakpovi, Erectogenic, antihypertensive, antidiabetic, anti–oxidative properties and phenolic compositions of Almond Fruit (Terminalia catappa L.) Parts (Hull and Drupe)–in vitro, *J. Food Biochem.*, 2017, **41**, e12309–e12320.

54 M. Akyuz, L. Yabo-Dambagi, T. Kilic and A. Cakir, Antidiabetic, neuroprotective and antioxidant potentials of different parts of Pistacia terebinthus fruits, *S. Afr. J. Bot.*, 2022, **147**, 443–456.

55 R. Attaallah, D. Elfadil and A. Amine, Screening study of enzymatic inhibition of medicinal plants for the treatment

of diabetes using a glucometer biosensor approach and optical method, *J. Herb. Med.*, 2021, **28**, 100441–100448.

56 T. S. de Souza, F. F. Dias, J. P. S. Oliveira, J. M. de Moura Bell and M. G. B. Koblitz, Biological properties of almond proteins produced by aqueous and enzyme-assisted aqueous extraction processes from almond cake, *Sci. Rep.*, 2020, **10**, 1–12.

57 X. Gu, T. Gao, Y. Hou, D. Li and L. Fu, Identification and characterization of two novel α-glucosidase inhibitory peptides from almond (*Armeniaca sibirica*) oil manufacture residue, *LWT–Food Sci. Technol.*, 2020, **134**, 110215–110223.

58 M. R. Loizzo, R. Tundis, M. Leporini, G. D'Urso, R. Gagliano Candela, T. Falco, S. Piacente, M. Bruno and F. Sottile, Almond (Prunus dulcis cv. casteltermini) skin confectionery by-products: New opportunity for the development of a functional blackberry (Rubus ulmifolius schott) jam, *Antioxidants*, 2021, **10**, 1218–1237.

59 V. E. Manhivi, R. M. Slabbert and D. Sivakumar, Co-ingestion of natal plums (Carissa macrocarpa) and Marula nuts (Sclerocarya birrea) in a snack bar and its effect on phenolic compounds and bioactivities, *Molecules*, 2022, **27**, 310–324.

60 L. Noguera-Artiaga, M. D. Salvador, G. Fregapane, J. Collado-González, A. Wojdyło, D. López-Lluch and Á. A. Carbonell-Barrachina, Functional and sensory properties of pistachio nuts as affected by cultivar, *J. Sci. Food Agric.*, 2019, **99**, 6696–6705.

61 L. L. Pino Ramos, F. Jiménez-Aspee, C. Theoduloz, A. Burgos-Edwards, R. Domínguez-Perles, C. Oger, T. Durand, Á. Gil-Izquierdo, L. Bustamante, C. Mardones, K. Márquez, D. Contreras and G. Schmeda-Hirschmann, Phenolic, oxylipin and fatty acid profiles of the Chilean hazelnut (Gevuina avellana): Antioxidant activity and inhibition of pro-inflammatory and metabolic syndrome-associated enzymes, *Food Chem.*, 2019, **298**, 125026–125038.

62 M. E. Rusu, I. Fizeşan, A. Pop, A.-M. Gheldiu, A. Mocan, G. Crişan, L. Vlase, F. Loghin, D.-S. Popa and I. Tomuta, Enhanced recovery of antioxidant compounds from hazelnut (Corylus avellana L.) involucre based on extraction optimization: Phytochemical profile and biological activities, *Antioxidants*, 2019, **8**, 460–481.

63 J. Wang, K. Du, L. Fang, C. Liu, W. Min and J. Liu, Evaluation of the antidiabetic activity of hydrolyzed peptides derived from Juglans mandshurica Maxim. fruits in insulin–resistant HepG2 cells and type 2 diabetic mice, *J. Food Biochem.*, 2018, **42**, e12518–e12526.

64 J. Wang, T. Wu, L. Fang, C. Liu, X. Liu, H. Li, J. Shi, M. Li and W. Min, Anti-diabetic effect by walnut (Juglans mandshurica Maxim.)-derived peptide LPLLR through inhibiting α-glucosidase and α-amylase, and alleviating insulin resistance of hepatic HepG2 cells, *J. Food Biochem.*, 2020, **69**, 103944–103956.

65 M. f. Zhu, Z. c. Tu, L. Zhang and H. Liao, Antioxidant, metabolic enzymes inhibitory ability of Torreya grandis kernels, and phytochemical profiling identified by HPLC–QTOF–MS/MS, *J. Food Biochem.*, 2019, **43**, e13043–e1342.

66 S. Sut, S. Dall'Acqua, K. Bene, S. B. di Marco, K. I. Sinan, M. F. Mahomoodally, M. C. N. Picot-Allain and G. Zengin, Ricinodendron heudelotii (Baill.) Heckel stem barks and seed extracts, a native food plant from Africa: Characterization by NMR and HPLC-DAD-ESI-MSn, *Food Res. Int.*, 2020, **129**, 108877–108886.

67 S. Shi, J. Li, J. Sun, J. Yu and S. Zhou, Phylogeny and classification of Prunus sensu lato (Rosaceae), *J. Integr. Plant Biol.*, 2013, **55**, 1069–1079.

68 Y. Ren, K. Liang, Y. Jin, M. Zhang, Y. Chen, H. Wu and F. Lai, Identification and characterization of two novel α-glucosidase inhibitory oligopeptides from hemp (Cannabis sativa L.) seed protein, *J. Funct. Foods*, 2016, **26**, 439–450.

69 L. Sun and M. Miao, Dietary polyphenols modulate starch digestion and glycaemic level: a review, *Crit. Rev. Food Sci. Nutr.*, 2020, **60**, 541–555.

70 L. Shai, S. Magano, S. Lebelo and A. Mogale, Inhibitory effects of five medicinal plants on rat alpha-glucosidase: Comparison with their effects on yeast alpha-glucosidase, *J. Med. Plant Res.*, 2011, **5**, 2863–2867.

71 S. H. Kim, S. H. Jo, Y. I. Kwon and J. K. Hwang, Effects of onion (Allium cepa L.) extract administration on intestinal α-glucosidases activities and spikes in postprandial blood glucose levels in SD rats model, *Int. J. Mol. Sci.*, 2011, **12**, 3757–3769.

72 W. Wang, H. Xu, H. Chen, K. Tai, F. Liu and Y. Gao, In vitro antioxidant, anti-diabetic and antilipemic potentials of quercetagetin extracted from marigold (Tagetes erecta L.) inflorescence residues, *J. Food Sci. Technol.*, 2016, **53**, 2614–2624.

73 S. Chiba, Molecular mechanism in alpha-glucosidase and glucoamylase, *Biosci. Biotechnol. Biochem.*, 1997, **61**, 1233–1239.

74 T. Matsui, C. Yoshimoto, K. Osajima, T. Oki and Y. Osajima, In vitro survey of alpha-glucosidase inhibitory food components, *Biosci. Biotechnol. Biochem.*, 1996, **60**, 2019–2022.

75 N. Promyos, P. Temviriyanukul and U. Suttisansanee, Evaluation of α-glucosidase inhibitory assay using different sub-classes of flavonoids, *Curr. J. Appl. Sci. Technol.*, 2017, **17**, 172–180.

76 E. H. Van Beers, H. A. Büller, R. J. Grand, A. W. Einerhand and J. Dekker, Intestinal brush border glycohydrolases: structure, function, and development, *Crit. Rev. Biochem. Mol. Biol.*, 1995, **30**, 197–262.

77 E. Barber, M. J. Houghton, R. Visvanathan and G. Williamson, Measuring key human carbohydrate digestive enzyme activities using high-performance anion-exchange chromatography with pulsed amperometric detection, *Nat. Protoc.*, 2022, **17**, 2882–2919.

78 R. Visvanathan, M. J. Houghton and G. Williamson, Maltoheptaoside hydrolysis with chromatographic detection and starch hydrolysis with reducing sugar analysis: Comparison of assays allows assessment of the roles of direct α-amylase inhibition and starch complexation, *Food Chem.*, 2021, **343**, 128423–128436.

79 R. S. Teixeira, A. S. da Silva, V. S. Ferreira-Leitão and E. P. da Silva Bon, Amino acids interference on the quanti-

fication of reducing sugars by the 3,5-dinitrosalicylic acid assay mislead carbohydrase activity measurements, *Carbohydr. Res.*, 2012, **363**, 33–37.

80 C. Lankatillake, S. Luo, M. Flavel, G. B. Lenon, H. Gill, T. Huynh and D. A. Dias, Screening natural product extracts for potential enzyme inhibitors: protocols, and the standardisation of the usage of blanks in α-amylase, α-glucosidase and lipase assays, *Plant Methods*, 2021, **17**, 3–21.

81 M. Qasim, I. Aziz, M. Rasheed, B. Gul and M. A. Khan, Effect of extraction solvents on polyphenols and antioxidant activity of medicinal halophytes, *Pak. J. Bot.*, 2016, **48**, 621–627.

82 S. F. Sulaiman, A. A. B. Sajak, K. L. Ooi and E. M. Seow, Effect of solvents in extracting polyphenols and antioxidants of selected raw vegetables, *J. Food Compos. Anal.*, 2011, **24**, 506–515.

83 J. Shinde, T. Taldone, M. Barletta, N. Kunaparaju, B. Hu, S. Kumar, J. Placido and S. W. Zito, Alpha-glucosidase inhibitory activity of Syzygium cumini (Linn.) Skeels seed kernel in vitro and in Goto-Kakizaki (GK) rats, *Carbohydr. Res.*, 2008, **343**, 1278–1281.

84 T. Matsui, T. Tanaka, S. Tamura, A. Toshima, K. Tamaya, Y. Miyata, K. Tanaka and K. Matsumoto, alpha-Glucosidase inhibitory profile of catechins and theaflavins, *J. Agric. Food Chem.*, 2007, **55**, 99–105.